Citi's Six-Stock SMid Biotech Note: Why the Buy-Buy-Buy-Buy-Buy-Neutral Pattern Is the Sector Inflection
Citi initiated coverage on six SMid biotechs last Monday. Five Buys. One Neutral. The pattern, not the targets, is the sector call long-only generalists missed.
The note arrived from Citigroup last Monday morning and the market spent most of the week reading it as six stock picks. It was not six stock picks. It was a sector inflection that, in our view, has been hidden in plain sight since the start of the year and has finally been formally underwritten by a bulge-bracket research desk. Eric Joseph, Citi's SMid biotech analyst, initiated coverage on six names: Alnylam Pharmaceuticals, Ascendis Pharma, BioMarin Pharmaceutical, Cytokinetics, and Ionis Pharmaceuticals — all Buy. The sixth, BridgeBio Pharma, came at Neutral. The Buy-Buy-Buy-Buy-Buy-Neutral pattern is what makes the call credible. Citi is signaling competitive selectivity within a cohort it now believes is collectively investable again. That is a different kind of analyst note than the ones the sell-side has issued on this group for three years.
SMid biotech has been the U.S. equity market's most unloved corner since the 2022 IPO collapse and the consensus 2023 conclusion that the sector was "uninvestable." The XBI biotech ETF is up roughly 12% year-to-date in 2026. It is still about 50% below its 2021 peak. Macro investors stopped paying attention in 2023 and have not reopened the file. Joseph's framing in the initiation note is the sentence that should pull them back in.
"Considering the past 12+ months, characterized by notably successful product launches, recognition of clinical successes, robust mergers and acquisitions activity in the sector, coupled with a more stable U.S. regulatory and drug pricing environment, we maintain a positive perspective on the broader commercial SMid Biotech." — Eric Joseph, Citigroup biotech analyst, SMid biotech initiation note, May 18, 2026.
Four conditions are doing the work in that sentence. The "more stable U.S. regulatory and drug pricing environment" is a reference to the post-Inflation Reduction Act regime stabilizing and, separately, to the FDA having worked through the post-pandemic backlog of biologic approvals. The "successful product launches" line refers to a cohort of 2024-2025 launches that have now produced two to three quarters of in-market data — Ionis's Tryngolza, Cytokinetics's Mykvorzo, several rare-disease franchises at Alnylam and BioMarin. The "robust M&A activity" line refers to a sequence that includes the Lilly-Verve deal, Sanofi-Vigil, J&J-Ambrx, Novartis-Tourmaline, and a clear acceleration in mid-cap targeting through the back half of 2025. The "recognition of clinical successes" is the post-readout repricing that has happened quietly across this cohort in the past 90 days without front-page coverage.
What the Ionis and Cytokinetics calls actually do
The two names that drew the most attention — Ionis at a $115 price target (52% upside from the $75 area where the stock traded into the note) and Cytokinetics at $99 (29% upside from $76) — are doing different jobs in the same sector call. Ionis is the platform validation. Cytokinetics is the commercial proof. On Ionis, Joseph wrote: "With its ASO platform validated multiple times, we're optimistic about Ionis' shift towards commercialization and capturing more value from its proprietary pipeline. We are particularly bullish on the peak potential for Tryngolza ahead of its sHTG label expansion in the near term, bolstered by higher-margin rare disease opportunities from Dawnzera and zilganersen." That sentence does three things. It declares the antisense oligonucleotide platform de-risked. It elevates Tryngolza — Ionis's first fully owned U.S. launch — from a single-product story to a precedent for the next four years of commercial transitions. And it signals that the partnered HORIZON Lp(a) readout (with Novartis), expected in the next twelve months, is now the asymmetric option the buy-side should be paying for.
On Cytokinetics, Joseph said: "We are optimistic about the launch and long-term commercial prospects of Mykvorzo in oHCM, given its positive reception among cardiologists and its distinct profile compared to Camzyos. More immediately relevant, following the topline results from ACACIA-HCM, we believe shares undervalue its risk-adjusted expansion opportunities into non-obstructive disease." This is the read on the Camzyos-Cytokinetics duopoly emerging in obstructive hypertrophic cardiomyopathy after the ACACIA-HCM readout in late Q1, with full data at the ESC Congress on August 28-31. Cytokinetics has, in three quarters, gone from a single-trial story to a commercial launch plus a credible Phase 3 expansion into non-obstructive HCM that would roughly double the addressable population. Joseph is telling clients the market is paying for one of those two assets and getting the other roughly for free.
The Neutral on BridgeBio is the most important rating in the note
Citi initiating BridgeBio at Neutral the same day it initiated five peers at Buy is the analytically credible move. BridgeBio's ATTR-CM franchise (acoramidis) sits in a market where Pfizer's tafamidis is the entrenched leader and where Alnylam's vutrisiran is now also approved for cardiomyopathy. The competitive dynamic is what Joseph priced. The Neutral does not say BridgeBio is a bad business. It says, in the standard sell-side grammar, that the path to peak revenue runs through the most contested cardiomyopathy franchise in the sector, against two well-resourced competitors, and that the current multiple already reflects what the model can support. The reason this matters for the sector call is that it tells clients the Buy ratings are not bull-market reflexes. They are competitive-position calls inside a re-rated sector.
The M&A multiple is what the call really prices
The Buy targets imply 30-50% upside. The Wall Street consensus targets imply 25-40%. The gap between Citi's targets and consensus is the M&A premium that has not yet been priced. Joseph's fourth sentence, which most of the post-note coverage skipped, is the one that frames the duration of the call: "We believe current valuations are underestimating Ionis' relative strength and influence among platform-enabled biotechs, and the potential to attract broader investor interest as it nears free cash flow generation by 2028." Free cash flow generation by 2028 is the inflection that moves a SMid biotech from a sector-rotation trade into a long-only generalist allocation. The 2028 cash-flow inflection across this cohort is, by our count, the single most under-discussed multi-year story in U.S. healthcare equities.
The pharma majors have a parallel problem the call indirectly addresses. Merck, Pfizer, Bristol-Myers Squibb, and J&J face combined revenue cliffs from Keytruda, Eliquis, and several IRA-negotiated franchises through 2028-2030. They need biologic licenses. They are also paying premium multiples for SMid targets when they bid. That cross-current — large-cap pharma needing pipeline plus a sector trading at depressed multiples plus a clinical-data cadence that is finally working — is the M&A engine the sector call rests on.
What we would actually do
Two thoughts. First, the standard mistake on a six-stock initiation is to buy all six. That is not the trade. The trade is to own the platforms, not the assets. Ionis and Alnylam are the two cleanest expressions of the platform-validation thesis. Cytokinetics is the cleanest expression of the commercial-launch thesis. Ascendis and BioMarin are sub-portfolio-construction decisions inside rare disease that depend on individual asset views. BridgeBio is the contested franchise that Citi was right to fade.
Second, the sector trade is more interesting than the picks. SMid biotech is mid-recovery, not late-cycle. The Citi note is, in our view, the first major sell-side desk to formally close the 2023 "uninvestable" chapter. Other desks will follow within four to six weeks. Generalist long-only buyers will respond not to the note itself but to the cascade of confirming notes that follows it. That is the window in which the sector multiple re-rates. By the time the second Citi-equivalent note prints, the easy beta is gone.
Our view
The Citi initiation reads on first pass as a stock note. On second pass, it is the cleanest sector signal U.S. biotech has had since the 2024 GLP-1 wave finished pulling capital out of the rest of the cohort. The thing to do is start sizing the exposure now, at the multiple, and let the cascade of confirming sell-side coverage and the M&A cadence do the work over the next twelve to eighteen months. The mistake is to wait for the headline narrative to turn. By then, the names Joseph initiated last Monday will be priced through their consensus targets, and the easier beta — XBI itself — will already have moved.
This note is a research view from Solomon Grey Capital. It is not investment advice and does not constitute a recommendation to buy or sell any security or asset. Information current as of May 25, 2026, 7:00 a.m. HKT.
